Scinai Immunotherapeutics Ltd.(SCNI)Earnings, Financials & Key Ratios
SCNI•NASDAQ
$0.26
Price updated Jul 7, 2026
AboutScinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.Show more
- Revenue$1M+99.2%
- EBITDA-$6M+12.4%
- Net Income-$8M-273.2%
- EPS (Diluted)-3.60-160.0%
- Gross Margin-202.29%-129.5%
- EBITDA Margin-466.9%+56.0%
- Operating Margin-575.29%+56.2%
- Net Margin-633.64%-186.9%
- ROE-91.89%-151.8%
SCNI Price & Volume
Scinai Immunotherapeutics Ltd. (SCNI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Burn Challenges Asset Heavy Model
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Scinai Immunotherapeutics faces a precarious outlook as its reliance on non-recurring service contracts fails to offset the high fixed-cost burden of its $14.0M net property, plant, and equipment base.
- While the company has managed to improve its equity position to $11.8M as of 2026Q1, the persistent disconnect between accounting net income and operating cash flow suggests that the firm remains fundamentally dependent on external capital.
- Investors should monitor the company's ability to achieve sustainable throughput in its Jerusalem facility, as current liquidity levels remain insufficient to cover ongoing operational deficits.
Verdict Logic
the company's $3.1M cash position remains insufficient to support its ongoing operational burn rate, which has resulted in consistent negative free cash flow across the last ten quarters.
SCNI Growth Metrics
Scinai Immunotherapeutics Ltd. (SCNI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM224.49%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-176.75%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM63913.33%
Return on Capital
10 Years-54.9%
5 Years-60.22%
3 Years-60.26%
Last Year-69.57%
Peers Comparison
Key metrics vs top competitors for Scinai Immunotherapeutics Ltd. (SCNI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.26 | $339.23K | -0.07 | 99.24% | -633.64% | -91.89% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $1.06 | $38.63M | -4.61 | -64.74% | -245.12% | -1004.96% | — | |
| $1.59 | $25.11M | -0.91 | 77.78% | -9202% | -53.86% | — | |
| $0.55 | $133.16M | 7.86 | 726.68% | 14.51% | 61.43% | — | |
| $1.44 | $70.88M | -6.00 | — | -1964.35% | -0.12% | — |
Compare SCNI vs Peers
Scinai Immunotherapeutics Ltd. (SCNI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SCNI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SCNI Frequently Asked Questions
Scinai Immunotherapeutics Ltd. (SCNI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Scinai Immunotherapeutics Ltd.'s revenue?
Scinai Immunotherapeutics Ltd. (SCNI) reported $1.5M in revenue for fiscal year 2025.
How fast is Scinai Immunotherapeutics Ltd. growing?
Scinai Immunotherapeutics Ltd. (SCNI) grew revenue by 99.2% over the past year. This is strong growth.
Is SCNI profitable?
Scinai Immunotherapeutics Ltd. (SCNI) reported a net loss of $2.8M for fiscal year 2025.
Dividend & Returns
What is SCNI's return on equity?
Scinai Immunotherapeutics Ltd. (SCNI) has a return on equity (ROE) of -91.9%. Negative ROE indicates the company is unprofitable.
What is Scinai Immunotherapeutics Ltd.'s free cash flow?
Scinai Immunotherapeutics Ltd. (SCNI) had negative free cash flow of $5.1M in fiscal year 2025, likely due to heavy capital investments.